Lazarus Naturals Brand Spotlight: Employee-Owned CBD With a Mission
Lazarus Naturals Brand Spotlight: Employee-Owned CBD With a Mission Lazarus Naturals does something unusual in the CBD industry: it sells...
Read moreKanibi has built a reputation on transparency in the CBD market. Every batch undergoes third-party lab testing for potency, contaminants, and heavy metals. Their testing extends beyond legal minimums—they test for microbial contamination, pesticides, and residual solvents. Kanibi publishes COAs (Certificates of Analysis) directly on product pages, allowing customers to verify exactly what they’re purchasing. This level of transparency is rare in the CBD industry.
Kanibi offers full-spectrum, broad-spectrum, and isolate CBD products. Their full-spectrum tinctures contain the complete cannabinoid profile plus beneficial terpenes. Softgels provide convenient dosing with consistent potency. Topical creams are formulated with additional skin-supporting ingredients. Gummies offer a tasty delivery method, though with lower bioavailability than oils. All products are non-GMO and derived from U.S.-grown hemp.
Kanibi’s pricing is mid-to-premium range, reflecting quality sourcing and testing costs. A 1000mg full-spectrum bottle costs $65-75, or about $0.065-0.075 per mg of CBD. This is competitive for their quality tier. Subscription discounts bring costs down by 10-20%, improving value. Compare to budget brands ($0.03-0.04/mg) and premium medical-grade options ($0.10+/mg) to assess value for your budget.
Customers consistently report satisfaction with Kanibi’s products. Pain relief feedback averages 7.5/10 across reviews. Sleep improvement is noted by 70% of users trying their sleep formulas. Anxiety reduction is reported by 65% of daily users. No significant side effects are commonly reported. Customer service is responsive and knowledgeable, which builds confidence in the brand.

Interested in finding out more about what’s happening in the world of CBD and Medicinal Cannabis?
Head to CBD World News for the latest scientific research, clinical trials, and business news.
Abstract: Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that...
Read moreCredits: Albert Batalla†, Hella Janssen†, Shiral S. Gangadin and Matthijs G. Bossong († These authors contributed equally to this work.)...
Read moreAuthors: Kimberly A. Babson1 & James Sottile 2 & Danielle Morabito1 Publish Date: 27 March 2017 Published by: Springer Science+Business...
Read more